ST-17 Clone Detection via Segmented Immunological and Molecular Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting highly virulent Group B Streptococcus (GBS) ST-17 clones are time-consuming and not suitable for routine use in obstetric settings, failing to distinguish these strains from other GBS serotypes, which limits targeted antibiotic prophylaxis and neonatal infection management.
Innovation Solution
Identification of a specific allele of the gbs2018 gene, along with corresponding polynucleotides, polypeptides, and antibodies, enables rapid and specific detection of ST-17 strains through specific polynucleotide sequences and epitope-based detection methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If culture method is used to detect GBS, then identification of GBS members is efficient, but distinction of high-virulence clones from others is not achieved
Solution Approach 1:
The invention segments the detection process into two distinct stages: first, a rapid immunological screening using serotype-specific antibodies to identify GBS presence and serotype; second, a molecular confirmation step using PCR with sequence-specific primers to distinguish ST-17 clones. This segmentation allows the system to achieve high precision by combining the sensitivity of cultural methods with the specificity of molecular techniques, while maintaining operational simplicity through a stepwise approach.
Solution Approach 2:
The invention introduces serotype-specific antibodies as an intermediary tool that bridges the gap between rapid detection and precise strain identification. These antibodies serve as a mediator that can rapidly screen for GBS presence and serotype classification, thereby filtering samples that require further molecular analysis. This intermediary approach enables the system to focus resources on distinguishing high-virulence clones only when necessary, improving overall detection efficiency without compromising precision.
2Measurement precision
If molecular epidemiological methods are used, then characterization of phylogenetic lineages is accurate, but detection process becomes time-consuming and not suitable for routine use
Solution Approach 1:
The invention applies preliminary action by performing serotype-specific immunological screening before molecular characterization. This preliminary step using serotype-specific antibodies rapidly identifies GBS presence and serotype classification, pre-filtering samples to determine which ones require further molecular analysis. By performing this preliminary action, the system achieves accurate strain characterization only when necessary, thereby maintaining high productivity for routine screening while preserving the ability to perform detailed molecular epidemiological analysis when needed.
Solution Approach 2:
The invention implements partial action by applying molecular epidemiological methods selectively rather than universally. Instead of performing time-consuming molecular characterization on all GBS samples, the system applies this partial molecular analysis only to samples that test positive for high-risk serotypes in the preliminary immunological screen. This partial application of molecular methods maintains high strain characterization accuracy for relevant cases while dramatically improving overall detection speed and productivity for routine obstetric use.
3Reliability
If culture method is used, then GBS presence is detected, but targeted antibiotic prophylaxis cannot be implemented
Solution Approach 1:
The invention applies local quality by implementing strain-specific detection capabilities at the molecular level while maintaining routine cultural methods for general GBS surveillance. The system uses serotype-specific antibodies and sequence-specific PCR primers tailored to ST-17 clones, providing localized, targeted detection exactly where high-virulence strain identification is needed. This local quality enhancement enables reliable detection of GBS presence through culture while simultaneously providing the specific strain information necessary for targeted antibiotic prophylaxis decisions.
Solution Approach 2:
The invention achieves universality by creating a dual-purpose detection system that can simultaneously perform routine GBS screening and high-virulence clone identification. The immunological screening reagents and molecular confirmation assays are designed to work within the existing obstetric workflow, allowing the same system to provide both general GBS detection for public health surveillance and specific ST-17 identification for targeted prophylaxis. This multi-functionality ensures that the system maintains reliable detection capability while enabling ease of operation for customized prophylaxis strategies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Facilitates rapid and efficient detection of ST-17 strains, allowing for targeted antibiotic prophylaxis and improved neonatal infection management by distinguishing ST-17 clones from other GBS serotypes, reducing antibiotic use and antimicrobial resistance.
Implementation Method 1
a polynucleotide hybridizing in stringent conditions with the gene of a)
Data Source
AI summary
The present invention relates to polynucleotides enabling the rapid, simple and specific detection of Group B Streptococcus highly-virulent ST-17 clones. The present invention also relates to the polypeptides encoded by the polynucleotides, as well as to antibodies directed or raised against the polypeptides. The present invention also relates to kits and methods for the specific detection of Group B Streptococcus highly-virulent ST-17 clones, using the polynucleotides, the polypeptides or the antibodies according to the invention.